| Literature DB >> 28979719 |
Yuji Kaneda1, Hiroshi Noda2, Yuhei Endo1, Nao Kakizawa1, Kosuke Ichida1, Fumiaki Watanabe1, Takaharu Kato1, Yasuyuki Miyakura1, Koichi Suzuki1, Toshiki Rikiyama1.
Abstract
AIM: To assess the usefulness of en bloc right hemicolectomy with pancreaticoduodenectomy (RHCPD) for locally advanced right-sided colon cancer (LARCC).Entities:
Keywords: Inflammatory adhesion; Locally advanced right-sided colon cancer; Malignant infiltration; Pancreaticoduodenectomy; Right hemicolectomy
Year: 2017 PMID: 28979719 PMCID: PMC5605337 DOI: 10.4251/wjgo.v9.i9.372
Source DB: PubMed Journal: World J Gastrointest Oncol
Patients’ characteristics
| 1 | Female | 73 | T | Du | 120.8 | 22.5 |
| 2 | Female | 74 | A | Du + Pa + St | 36.6 | 20.3 |
| 3 | Male | 70 | A | Du + Pa | 0.5 | 49.2 |
| 4 | Female | 57 | T | Du + Pa + Gb + SMV | 2.6 | 13.7 |
| 5 | Male | 47 | A | Du + Pa + SMV | 12.3 | 196.8 |
Tumor thrombosis in SMV. A: Ascending colon; T: Transverse colon; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; CT: Computed tomography; Du: Duodenum; St: Stomach; Pa: Pancreas; Gb: Gallbladder; SMV: Superior mesenteric vein.
Figure 1Preoperative computed tomography showing tumor thrombosis in the superior mesenteric vein in Case 5. T: Tumor; TT: Tumor thrombosis; PV: Portal vein; SPV: Splenic vein; SMV: Superior mesenteric vein; J1V: First jejunal vein; J2V: Second jejunal vein.
Surgical findings and complications
| 1 | PD + RHC + DP | Du | 406 | 940 | 35 | PF (B) |
| 2 | PD + RHC + SMVR | Du + Pa + St + SMV | 524 | 840 | 27 | PF (C) |
| 3 | PD + RHC | Du + Pa + Gb | 304 | 200 | 33 | PF (A), DGE |
| 4 | PD + RHC + SMVR | Du + Pa + Gb + SMV | 538 | 2760 | 36 | PF (A) |
| 5 | PD + RHC + SMVR | Du + Pa + SMV | 506 | 2470 | 39 | PF (A) |
Tumor thrombosis in SMV. OT: Operation time; OBL: Operative blood loss; DHS: Duration of hospital stay; PD: Pancreaticoduodenectomy; RHC: Right hemicolectomy; DP: Distal pancreatectomy; SMVR: Superior mesenteric vein resection; Du: Duodenum; St: Stomach; Pa: Pancreas; Gb: Gallbladder; SMV: Superior mesenteric vein; PF: Pancreatic fistula; DGE: Delayed gastric emptying.
Histological findings
| 1 | 4b | 0 | 1a (LYM | Du | Mod + NET | 0 |
| 2 | 4b | 1b | 1b (LYM | St | Muc | 0 |
| 3 | 4b | 0 | 0 | Du + Pa | Well | 0 |
| 4 | 4b | 0 | 0 | Du + Gb | Well | 0 |
| 5 | 4b | 1a | 1a (OTH | Du + Pa | Well | 0 |
Extra-regional lymph node metastasis (peripancreatic lymph node);
Extra-regional lymph node metastasis (periduodenal lymph node);
Tumor thrombosis in SMV. Mod: Moderately differentiated adenocarcinoma; Well: Well-differentiated adenocarcinoma; NET: Neuroendocrine tumor; Du: Duodenum; St: Stomach; Pa: Pancreas; Gb: Gallbladder.
Figure 2Histological findings revealing tumor thrombosis in the superior mesenteric vein in Case 2 (× 4). SMV: Superior mesenteric vein; TT: Tumor thrombosis.
Chemotherapy and outcomes
| 1 | Cape | 77 | - | 77 | Alive | |
| 2 | - | 5 | Cetu | 11 | Dead | LM |
| 3 | - | 95 | - | 95 | Alive | |
| 4 | - | 85 | - | 85 | Alive | |
| 5 | - | 1 | Cape + OX + Beva | 11 | Dead | LM |
ACT: Adjuvant chemotherapy; CT: Chemotherapy; DFS: Disease-free survival; OS: Overall survival; CD: Cause of death; LM: Liver metastasis; Cape: Capecitabine; Cetu: Cetuximab; Beva: Bevacizumab; OX: Oxaliplatin.